Gene therapy with adenovirus-delivered indoleamine 2,3-dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat

Journal of Gene Medicine

Volumn 13, Issue 7-8, 2011, Pages 373-381

  Vavrincova Yaghi, Diana ^a   Deelman, Leo E ^a   van Goor, Harry ^a   Seelen, Marc ^a   Kema, Ido P ^a   Smit van Oosten, Annemieke ^a   de Zeeuw, Dick ^a   Henning, Robert H ^a   Sandovici, Maria ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

3 dioxygenase; Adenovirus; Gene therapy; Indoleamine 2; Kidney; Transplantation

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; CREATININE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; INTERLEUKIN 2; KIDNEY INJURY MOLECULE 1; KYNURENINE; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN;

ACUTE GRAFT REJECTION; ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VIRAL GENE THERAPY;

ACTINS; ADENOVIRIDAE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; GRAFT REJECTION; HEK293 CELLS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MACROPHAGES; RATS; TRANSGENES; TRANSPLANTATION, HOMOLOGOUS;

ADENOVIRIDAE; RATTUS;

EID: 79960888410     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1584     Document Type: Article

References (54)

1. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235-242.
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
3. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005; 16: 1758-1774.
4. Patel R. Infections in recipients of kidney transplants. Infect Dis Clin North Am 2001; 15: 901-952.
5. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80: S254-S264.
6. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009; 69: 2227-2243.
7. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774.
8. King NJ, Thomas SR. Molecules in focus: indoleamine 2, 3-dioxygenase. Int J Biochem Cell Biol 2007; 39: 2167-2172.
9. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193.
10. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-1372.
11. Grohmann U, Fallarino F, Bianchi R, et al. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 2003; 198: 153-160.
12. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5: 2516-2522.
13. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176: 6752-6761.
14. Mellor AL, Baban B, Chandler P, et al. Cutting edge: induced indoleamine 2, 3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171: 1652-1655.
15. Haniffa MA, Wang XN, Holtick U, et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007; 179: 1595-1604.
16. Beutelspacher SC, Tan PH, McClure MO, Larkin DF, Lechler RI, George AJ. Expression of indoleamine 2, 3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am J Transplant 2006; 6: 1320-1330.
17. Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 2003; 9: 1269-1274.
18. Hayashi T, Beck L, Rossetto C, et al. Inhibition of experimental asthma by indoleamine 2, 3-dioxygenase. J Clin Invest 2004; 114: 270-279.
19. Grohmann U, Volpi C, Fallarino F, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007; 13: 579-586.
20. Fallarino F, Volpi C, Zelante T, et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol 2009; 183: 6303-6312.
21. Löb S, Königsrainer A. Role of IDO in organ transplantation: promises and difficulties. Int Rev Immunol 2009; 28: 185-206.
22. Cook CH, Bickerstaff AA, Wang JJ, et al. Spontaneous renal allograft acceptance associated with 'regulatory' dendritic cells and IDO. J Immunol 2008; 180: 3103-3112.
23. Brandacher G, Cakar F, Winkler C, et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007; 71: 60-67.
24. Sandovici M, Deelman LE, Smit-van Oosten A, et al. Enhanced transduction of fibroblasts in transplanted kidney with an adenovirus having an RGD motif in the HI loop. Kidney Int 2006; 69: 45-52.
25. Diamond JR, Tilney NL, Frye J, et al. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation 1992; 54: 710-716.
26. Wyburn K, Wu H, Yin J, Jose M, Eris J, Chadban S. Macrophage-derived interleukin-18 in experimental renal allograft rejection. Nephrol Dial Transplant 2005; 20: 699-706.
27. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
28. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
29. Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther 1999; 6: 1336-1339.
30. Meijering BD, van der Wouden EA, Pelgröm V, Henning RH, Sharma K, Deelman LE. TGF-beta inhibits Ang II-induced MAPK p44/42 signaling in vascular smooth muscle cells by Ang II type 1 receptor downregulation. J Vasc Res 2009; 46: 459-468.
31. de Jong WH, Smit R, Bakker SJ, de Vries EG, Kema IP. Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 603-609.
32. Sandovici M, Deelman LE, van Goor H, Helfrich W, de Zeeuw D, Henning RH. Adenovirus-mediated interleukin-13 gene therapy attenuates acute kidney allograft injury. J Gene Med 2007; 9: 1024-1032.
33. Badid C, Desmouliere A, Babici D, et al. Interstitial expression of alpha-SMA: an early marker of chronic renal allograft dysfunction. Nephrol Dial Transplant 2002; 17: 1993-1998.
34. Zhang PL, Rothblum LI, Han WK, Blasick TM, Potdar S, Bonventre JV. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int 2008; 73: 608-614.
35. Manchanda PK, Mittal RD. Analysis of cytokine gene polymorphisms in recipient's matched with living donors on acute rejection after renal transplantation. Mol Cell Biochem 2008; 311: 57-65.
36. Atalar K, Afzali B, Lord G, Lombardi G. Relative roles of Th1 and Th17 effector cells in allograft rejection. Curr Opin Organ Transplant 2009; 14: 23-29.
37. Gorczynski RM. Role of cytokines in allograft rejection. Curr Pharm Des 2001; 7: 1039-1057.
38. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342-2351.
39. Nagano H, Nadeau KC, Takada M, Kusaka M, Tilney NL. Sequential cellular and molecular kinetics in acutely rejecting renal allografts in rats. Transplantation 1997; 63: 1101-1108.
40. Einecke G, Mengel M, Hidalgo L, Allanach K, Famulski KS, Halloran PF. The early course of kidney allograft rejection: defining the time when rejection begins. Am J Transplant 2009; 9: 483-493.
41. Liu H, Liu L, Liu K, Bizargity P, Hancock WW, Visner GA. Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2, 3-dioxygenase-dependent immune suppression. J Immunol 2009; 183: 1022-1031.
42. Li J, Meinhardt A, Roehrich ME, et al. Indoleamine 2, 3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Heart Circ Physiol 2007; 293: H3415-3423.
43. Jalili RB, Rayat GR, Rajotte RV, Ghahary A. Suppression of islet allogeneic immune response by indoleamine 2, 3-dioxygenase-expressing fibroblasts. J Cell Physiol 2007; 213: 137-143.
44. Beutelspacher SC, Pillai R, Watson MP, et al. Function of indoleamine 2, 3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006; 36: 690-700.
45. Laurence JM, Wang C, Zheng M, et al. Overexpression of indoleamine dioxygenase in rat liver allografts using a high-efficiency adeno-associated virus vector does not prevent acute rejection. Liver Transpl 2009; 15: 233-241.
46. Vincenti F, de Andrés A, Becker T, et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int 2006; 19: 446-457.
47. Li R, Wei F, Yu J, Li H, Ren X, Hao X. IDO inhibits T-cell function through suppressing Vav1 expression and activation. Cancer Biol Ther 2009; 8: 1402-1408.
48. Yu G, Dai H, Chen J, et al. Gene delivery of indoleamine 2, 3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses. J Gene Med 2008; 10: 754-761.
49. Loong CC, Hsieh HG, Lui WY, Chen A, Lin CY. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002; 197: 322-332.
50. Djamali A, Samaniego M. Fibrogenesis in kidney transplantation: potential targets for prevention and therapy. Transplantation 2009; 88: 1149-1156.
51. Grimm PC, McKenna R, Nickerson P, et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 1999; 10: 1582-1589.
52. Hou W, Li S, Wu Y, Du X, Yuan F. Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis. Clin Exp Immunol 2009; 156: 363-372.
53. Liu H, Liu L, Visner GA. Nonviral gene delivery with indoleamine 2, 3-dioxygenase targeting pulmonary endothelium protects against ischemia-reperfusion injury. Am J Transplant 2007; 7: 2291-2300.
54. Mohib K, Wang S, Guan Q, et al. Indoleamine 2, 3-dioxygenase expression promotes renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2008; 295: F226-F234.